I'm LongbridgeAI, I can summarize articles.Akeso (9926.HK) fell more than 6% in Hong Kong trading, last at HK$58.15.
The biotechnology industry index fell 2.6% over the same period.
Overseas partner Summit Therapeutics announced that the U.S. Food and Drug Administration issued a Complete Response Letter for the biologics license application of ivonescimab combined with platinum-based chemotherapy for second-line EGFR-mutated non-small cell lung cancer. The FDA noted that while the study met its primary endpoint of progression-free survival, overall survival did not show a statistically significant improvement, rendering the evidence of effectiveness insufficient.
Daiwa cut its price target on the stock to HK$120 from HK$140, while Citi lowered its target to HK$163. Nomura downgraded the shares to Neutral from Buy and reduced its price target to HK$94.
Based on public media reports. AI-generated; not investment advice.
